Lancet Neurology

Article	Citations
Diversity and inclusion in neurosurgery	3827
Score fluctuation might be associated with a higher placebo rate in the RAISE trial	785
The hidden unity of the mind	550
Treatment of asymptomatic carotid stenosis in SPACE-2	537
With thanks to our peer reviewers in 2022	506
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	440
Correction to Lancet Neurol 2025; 24: 65–76	410
The reality of multiple sclerosis assessment in middle-income countries	357
The debate on how to protect and restore brain health	341
Disparities in neurosurgical care for traumatic brain injury	338
Advanced consent for acute stroke trials	324
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	321
The challenge of pregnancy in women with multiple sclerosis	318
A neurological journey to save lives in Haiti	311
Medieval treatment of epilepsy in England	303
Lightning progress in child neurology in the past 20 years	282
Tanuja Chitnis: on role models, family, and multiple sclerosis	282
Spiralling towards an ending	266
Dancing with paper	228
Anatomy embroiders function in Purkinje cells	226
Malformations of cortical development as models of altered brain excitability	212
Maeike Zijlmans	211
Vittorio Marchi's staining	203
The wisdom of our mentors: clinical pearls in movement disorders	195
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	195

Pseudomedicine for sports concussions in the USA	193
Transforming amyotrophic lateral sclerosis into a liveable disease	190
Elevating the wellbeing of neurologists	189
Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke	173
Licence to practise	169
Our Dementia Choir hits the right notes	168
CGRP-targeted drugs for migraine: still many uncertainties	162
Fetal exposure to antiseizure medications: reassurance and concerns	160
Elisaveta Sokolov	157
Sex, gender, and the cost of neurological disorders	153
Journey down memory lane	146
V Wee Yong: a journey of rediscovery	143
Giuseppe Citerio's neurocucina	142
Tatyana Shelkovnikova	141
Form and function in the brain	141
The social network of functional neurological disorder	137
COP27 Climate Change Conference: urgent action needed for Africa and the world	136
A new classification for diagnosis of optic neuritis	134
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease – Authors' reply	131
Application of diagnostic criteria for optic neuritis	131
The evolving paradigm of Alzheimer's disease diagnosis	131
The link between blood pressure and Alzheimer's disease	130
Multiple sclerosis: two decades of progress	128
α-synuclein seed amplification in Parkinson‘s disease	128
Traumatic brain injury research: homogenising heterogeneity	128
Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage	123
Appropriate selection of participants for clinical trials in epilepsy	122
Forging ahead in haemorrhagic stroke research	121
A neurotransmitter with a fascinating story	118
What we remember	116
Association of Pick's disease with the MAPT H2 haplotype	111
PROMISE of low-cost immunosuppressants for myasthenia gravis	108
The predictive value and clinical use of the neurological pupillary index – Authors' reply	105
Monitoring patients with severe traumatic brain injury	103
Innovation in the prevention of neurological diseases	101
A contentious FDA ruling for Alzheimer's disease	100
Dementia care: beyond a diagnosis	99
Huntington's disease: disappointments and new beginnings	96
Climate change and neurology: time to talk and to act	96
Lessons and future directions for GBA1-targeting therapies	95
Georgios Tsivgoulis: in top gear	93
20th Anniversary photography competition: neurology for zoomers	92
Intracranial pressure monitoring and unfavourable outcomes	92
Headache in 2021: clinical, biological, and genetic advances	90
Leriglitazone: frustration and hope in adrenoleukodystrophy	89
Intra-arterial bone marrow mononuclear cells for stroke	88
The shortage of thrombolytics for stroke: a call for action	88
A disease-specific therapy in facioscapulohumeral muscular dystrophy	87
Treatment of asymptomatic carotid stenosis	81
Traumatic brain injury advances since 2017: what has changed?	81

Ischaemic stroke in 2024: progress on multiple fronts	80
Reconsidering prourokinase for acute ischaemic stroke	79
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	77
Jules Froment's neurological statuettes	77
Correction to Lancet Neurol 2024; 23: 393–403	76
Women in Neurosurgery: breaking barriers	76
Amyotrophic lateral sclerosis: a lesson in translation	75
Neurological disorders caused by novel non-coding repeat expansions: clinical features and differential diagnosis	75
Carotid artery overtreatment in the USA	73
Tom Solomon: world records, academic leadership, and emerging infections	73
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	72
Making brain health a global priority	71
WHO launches its Global Action Plan for brain health	70
Dementia diagnosis in the anti-amyloid era	69
Speculation on the transmissibility of Alzheimer's disease	67
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	66
The neuropsychiatry of Parkinson's disease: advances and challenges	66
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group	64
Neuromodulation in epilepsy: state-of-the-art approved therapies	64
Elinor Ben-Menachem: a talented risk-taker with great results	63
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials	63
Dementia research in 2022: advancing steadily on reflection	63
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial	63
Angela Vincent: a pioneer of immune-mediated disease	61
Multidisciplinary care for amyotrophic lateral sclerosis	61
Addressing neurological burden in the Americas	61
Concerns with the new biological research criteria for synucleinopathy	61
Cristina Tassorelli: making a difference in headache research	60
Apomorphine infusion for improving sleep in Parkinson's disease	60
Implications of the KIWE trial for low-income and lower-middle-income countries	60
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study	59
Autoimmune encephalitis: chasing a moving target	59
Health as a philosophical idea	58
γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational	57
Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-in	57
Amyloid removal and the appearance of brain volume loss	56
Considerations for future trials in cerebral cavernous malformations – Authors' reply	56
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	56
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study	56
CNS disease associated with enhanced type I interferon signalling	54
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	53
Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series	53
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	52
Could SARS-CoV-2 cause tauopathy?	52
Mitochondrial disease in adults: recent advances and future promise	52
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	51
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study	51
The East Asian Parkinson Disease Genomics Consortium	49
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	48
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	48
New therapies for Pompe disease: are we closer to a cure?	48
Cerebral amyloid angiopathy criteria: the next generation	48
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	47
Sleep function: an evolutionary perspective	47
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	46
Seizure prevention in patients with intracerebral haemorrhage	45
Moyamoya disease: diagnosis and interventions	45
Diagnosis and classification of optic neuritis	45
Multiple sclerosis progression: time for a new mechanism-driven framework	44
Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA	43
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3	43
Lecanemab slows Alzheimer's disease: hope and challenges	42
Advances in Alzheimer's disease research over the past two decades	42
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study	42
The relevance of social and commercial determinants for neurological health	41
Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis	40
Neuroscience highlights in 2022: cytoskeletal transport	39
Challenges of Parkinson's disease GWASs in African people	39
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	39
Kerstin Hellwig: educating on multiple sclerosis and pregnancy	39
The prognostic potential of pupillometry in patients with acute brain injury	39
Progression of cerebral amyloid angiopathy: a pathophysiological framework	38
Treatment of acute subdural haematoma – Authors' reply	38
The EyeVu Consortium for global neurosurgery	37
The African Dementia Consortium	37
Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention	37
Extended-interval dosing of natalizumab in NOVA – Authors' reply	37
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research	37
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	37
A spirited community that knows how to fight	36

Chronic effects of inflammation on tauopathies	36
Cardiovascular disease after traumatic brain injury: the heart of the matter	36
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses	36
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	35
Azathioprine and mycophenolate mofetil in myasthenia gravis – Authors' reply	34
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	34
Rare diseases: we need to think about climate change too	34
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	33
Treatment for Alzheimer's disease: time to get ready	33
CSF factors in memory function	33
The Brain Research Africa Initiative (BRAIN)	32
Management of atherosclerotic extracranial carotid artery stenosis	31
Has the time come to redefine Parkinson's disease?	30
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial	29
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	28
Inspiring the next generation	28
Integrated approach to stroke burden: are we doing enough?	27
Time to end the stigma of epilepsy	27
Effects of climate change on the brain: an environmental neurology perspective	26
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	26
Frank Longo: taking on Alzheimer's disease	25
The elusive foundations of creativity	25
Surgical treatment for chronic subdural haematoma	25
Carpal tunnel syndrome: updated evidence and new questions	23
Crossing the blood–brain barrier: emerging therapeutic strategies for neurological disease	23
Increasing diversity in dementia research	23
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	23
Drug resistance in epilepsy	23
A biological classification of Huntington's disease: the Integrated Staging System	22
Anti-CD19 CAR T cells for refractory myasthenia gravis	22
Correction to Lancet Neurol 2024; 23: 168–77	21
Differential diagnosis of suspected multiple sclerosis: global health considerations	21
Correction to Lancet Neurol 2021; 20: 762–72	21
Correction to Lancet Neurol 2021; 20: 1038–47	21
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia	21
Correction to Lancet Neurol 2022; 21: 42–52	21
RAB32 mutation in Parkinson's disease	21
Improving access to medicines for neurological disorders	20
Important considerations for children with non-dystrophic myotonia	20
Global burden of stroke: dynamic estimates to inform action	20
The Yaoundé Declaration	20
Correction to Lancet Neurology 2021; 19: 1033–42	19
Correction to Lancet Neurol 2022; published online Sept 29. https://doi.org/10.1016/ S1474-4422(22)00309-X	19
Nursing homes with a difference: the outdoors inside	19
Correction to Lancet Neurol 2021; 20: 703–04	19
Correction to Lancet Neurol 2021; 20: 448–59	19
Correction to Lancet Neurol 2023; 22: 1160–206	19
Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics	18
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial	18
Healthy brain in a healthy body	18
Walker's miracle of science	17
From film to philanthropy	17
Highlights in traumatic brain injury research in 2023	17
Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment	17
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	17
Anticoagulants to prevent recurrent non-cardioembolic stroke	17
Diabetes and Alzheimer's disease: shared genetic susceptibility?	17
Action needed on social and commercial determinants of neurological health – Authors' reply	16
Neurology is not a heartless business	16
Rigmor Højland Jensen: the headache warrior	16
Considering the neurological health needs of LGBTQIA people	16
A multipronged approach to advancing palliative care for people with intellectual disabilities	16
Prevention of dementia with holistic brain health	16
WHO considers multiple sclerosis treatments essential	16
Prioritising integration of palliative care to prevent suffering	15
Pierre Amarenco: the persistent pioneer	15
Trials in intracerebral haemorrhage: a path to success?	15
A chilly tale of dementia	15
Correction to Lancet Neurol 2019; 18: 329–31	15
Thank you to The Lancet Neurology's peer reviewers in 2022	15
Alzheimer's disease: a history revisited	15
Italy's actions on dementia	14
Asymptomatic carotid stenosis and stroke risk – Authors' reply	14
Targeting C9orf72 in people with ALS	14
Nutrition in acute stroke management: food for thought	14
A celebration of neurology in the 21st century	14
The promises and pitfalls of brain repair	14
Karen Duff: blazing a path in dementia research	14
Intracranial pressure monitoring in adult patients with traumatic brain injury: challenges and innovations	14
20 years of hammers, pins, and hope	14
Esme Ekizoglu Turgut	14
Sleep and sleep disorders in people with Parkinson's disease	13
Aspiring to restore arm and hand function after stroke	13
Daridorexant for insomnia disorder	13
A genetic basis for the severity of multiple sclerosis	13
Amyotrophic lateral sclerosis from genotoxins alone?	13
Mesenchymal stem cells for multiple sclerosis: hype or hope?	13
Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study	13
Credulity of exploratory trials for cerebral cavernous malformations	12
Turin as a neuroscience cradle	12
Märit Jensen	12
Alison Christy	12
Beyond the modular brain	12
Improving prognostication after severe brain injury	11
Advancing our knowledge about cerebral small vessel diseases	11